The paradox of immunotherapy in NASH-HCC

被引：0
|
作者：
Yao Peng
Chi Chun Wong
Jun Yu
机构：
[1] South China University of Technology,Department of Gastroenterology, Guangzhou First People’s Hospital
[2] The Chinese University of Hong Kong,Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK
来源：
Signal Transduction and Targeted Therapy | / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The paradox of immunotherapy in NASH-HCC
    Peng, Yao
    Wong, Chi Chun
    Yu, Jun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [2] Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH
    Geh, Daniel
    Gil, Erik Ramon
    Laszczewska, Maja
    Collins, Amy
    Luli, Saimir
    Cameron, Rainie
    Oakley, Fiona
    Leslie, Jack
    Reeves, Helen Louise
    Mann, Derek A.
    JOURNAL OF HEPATOLOGY, 2023, 78 : S538 - S539
  • [3] CXCR2 inhibition sensitises NASH-HCC to immunotherapy
    Leslie, Jack
    Mackey, John B. G.
    Jamieson, Thomas
    Reeves, Helen L.
    Llovet, Josep M.
    Leo, Carlin
    Bird, Thomas G.
    Sansom, Owen
    Mann, Derek A.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S385 - S386
  • [4] CXCR2 inhibition enables NASH-HCC immunotherapy
    Leslie, Jack
    Mackey, John B. G.
    Jamieson, Thomas
    Ramon-Gil, Erik
    Drake, Thomas M.
    Fercoq, Frederic
    Clark, William
    Gilroy, Kathryn
    Hedley, Ann
    Nixon, Colin
    Luli, Saimir
    Laszczewska, Maja
    Pinyol, Roser
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Haber, Philipp K.
    Andreu-Oller, Carmen
    Rahbari, Mohammad
    Fan, Chaofan
    Pfister, Dominik
    Raman, Shreya
    Wilson, Niall
    Muller, Miryam
    Collins, Amy
    Geh, Daniel
    Fuller, Andrew
    McDonald, David
    Hulme, Gillian
    Filby, Andrew
    Cortes-Lavaud, Xabier
    Mohamed, Noha-Ehssan
    Ford, Catriona A.
    Iraolagoitia, Ximena L. Raffo
    McFarlane, Amanda J.
    McCain, Misti, V
    Ridgway, Rachel A.
    Roberts, Edward W.
    Barry, Simon T.
    Graham, Gerard J.
    Heikenwalder, Mathias
    Reeves, Helen L.
    Llovet, Josep M.
    Carlin, Leo M.
    Bird, Thomas G.
    Sansom, Owen J.
    Mann, Derek A.
    GUT, 2022, 71 (10) : 2093 - 2106
  • [5] Molecular landscape of NASH-HCC
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 : 456 - 456
  • [6] Molecular landscape of NASH-HCC
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (07) : 456 - 456
  • [7] The role of hepatocyte TAZ in NASH and NASH-HCC
    Wang, Xiaobo
    Schwabe, Robert
    Tabas, Ira
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [8] T cell drivers in NASH-HCC
    O'Leary, Karen
    NATURE REVIEWS CANCER, 2021, 21 (06) : 341 - 341
  • [9] T cell drivers in NASH-HCC
    Karen O’Leary
    Nature Reviews Cancer, 2021, 21 : 341 - 341
  • [10] CXCR2 inhibition in NASH-HCC
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 415 - 415
12345